ABSTRACT
Background Previous studies have shown that elevated trimethylamine N-oxide (TMAO) was associated with a higher risk of diabetes mellitus (DM). Little is known about the relationship between dietary intake of choline, which is a major dietary precursor for gut microbiome-derived TMAO, and DM in the general population.
Objective The present study aims to explore the relationship between dietary choline intakes and DM in the United States (US) adult population.
Design Cross-sectional data were derived from the National Health and Nutrition Examination Survey (NHANES) 2007-2010 of 8621 individuals aged 20 years or older. Multivariable logistic regression models were used to determine odds ratios (ORs) and 95% confidence intervals (CIs) for DM of each quartile category of energy-adjusted choline intakes. The restricted cubic spline model was used for the dose-response analysis. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value of choline intake for predicting DM.
Results A linear dose-response relationship between dietary choline intakes and the odds of DM was found after adjustment for multiple potential confounding factors, p for linear =0.0002. With the lowest quartile category of choline as the reference, the multivariable-adjusted ORs and 95% CIs of the second, third, and highest quartile categories were 1.22 (0.98, 1.52), 1.26 (1.01, 1.56), and 1.42 (1.15, 1.77), respectively, p for trend =0.0024. Per 100 mg/d increase in energy-adjusted choline resulted in 15% (95% CI: 7%, 22%) higher odds of DM. The ROC analysis identified an energy-adjusted choline of 331.7 mg/d as the optimal cut-off value for predicting DM, with 52.5% sensitivity and 60.7% specificity.
Conclusion This study supports a positive and linear relationship between dietary choline intake and DM in the US adult population. Further studies are warranted to replicate our findings in other populations and elucidate the potential mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was not specifically funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Center for Health Statistics (NCHS) institutional review board approved the study protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this manuscript are de-identified and freely available to the public.
